Faruqi & Faruqi, LLP Conducts Investigation into Skye Bioscience for Investor Claims

Faruqi & Faruqi Investigates Claims on Behalf of Skye Bioscience Investors

New York, NY, November 21, 2025 – Faruqi & Faruqi, LLP, a prominent national securities law firm, has launched an investigation into potential claims against Skye Bioscience, Inc. This follows the revelation of concerning data regarding Skye's drug, nimacimab, which could have implications for investors who acquired securities in the company between November 4, 2024, and October 3, 2025.

Recent Developments

The investigation arises from Skye's announcement on October 6, 2025, detailing results from its Phase 2a clinical study of nimacimab. The study's primary endpoint of weight loss compared to a placebo was not met, and the drug's pharmacokinetic analysis indicated unexpectedly low drug exposure. Following this announcement, Skye's stock plummeted by 60%, closing at $1.90, down $2.85 per share. This sharp decline raised flags regarding possible violations of federal securities laws by Skye and its executives.

Legal Implications

Faruqi & Faruqi's investigation contends that Skye and its representatives may have misled investors by overstating the effectiveness and prospects of nimacimab. The firm’s partner, James (Josh) Wilson, encourages any investors who have suffered losses due to these developments to get in touch for a discussion about their legal rights. Given the potential fallout from these allegations, the deadline for investors to seek lead plaintiff status in a federal securities class action lawsuit is set for January 16, 2026.

Next Steps for Investors

Investors affected by Skye's poor clinical trial results are urged to contact Faruqi & Faruqi to navigate the complexities of this situation. Those who wish to participate in the class action can choose to appoint a lead plaintiff or remain a part of the class without active participation. The rights of all investors who opt to join the action remain intact, without prejudice to those who do not engage in the role of lead plaintiff.

Furthermore, the firm is calling upon whistleblowers, former employees, and shareholders with any information regarding Skye's business operations to come forward. Such insights might be critical in holding the company accountable and may potentially affect ongoing legal proceedings.

For anyone looking to learn more about the situation or to consult regarding their losses, they can visit Faruqi & Faruqi's website at www.faruqilaw.com/SKYE or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Conclusion

With the deadline approaching, affected investors have a critical opportunity to evaluate their options and take necessary action. The implications of Skye's recent trial results may be profound, and being informed is essential as these developments unfold. Faruqi & Faruqi, LLP stands prepared to assist those seeking accountability and justice in this matter, and as always, confidentiality in all communications with the firm is assured.